ELIFE:癌症研究通过可重复性实验

2017-06-29 佚名 中国生物技术网

一个旨在检测癌症生物学可重复性的项目近日公布了第二批验证结果,这一次它带来的是好消息:两篇重要癌症论文的绝大多数实验可以被重复。

一个旨在检测癌症生物学可重复性的项目近日公布了第二批验证结果,这一次它带来的是好消息:两篇重要癌症论文的绝大多数实验可以被重复。

最新可重复性研究于6月27日发表于开放获取在线生命科学期刊eLife,它们紧随今年1月对5篇论文进行可重复性验证之后。此前就高影响力癌症研究能否被重复的验证产生了矛盾的信息。

但在此次的两项新重复性实验中,仍有一个重要小鼠实验未能重复,《癌症生物学》可重复性项目负责人之一表示,这表明动物研究可重复性当前面临的问题。

这一不同寻常的计划受到两个制药公司报告的鼓励,相关报告称多达89%的临床生物医学研究在他们的实验室中站不住脚。该计划与实验室签订协议,就2010年到2012年间发表的约30篇高影响力癌症论文的关键实验进行可重复性验证。一些研究人员鼓励这一做法,但也有一些人担心合作实验室缺乏开展某些实验的专业技能以及先进的学术研究实验室,任何失败都会不公平地玷污这一领域。

今年1月,当首批5篇文章的可重复性研究公布后,批评人士对此表示担心。当时,仅有两篇研究可被重复,1项研究结果是负面的,另外两项研究结果因为小鼠肿瘤模型问题而被认为是并非确定性的。相关结论让一些专家认为生物医学领域正在遭遇可重复性危机。

现在,科学家的跟踪记录似乎正在提高。在其中一项新研究中,一家合作实验室确定了2010年发表于《癌症细胞》的一项研究的结果:在一些白血病和脑癌中发现的IDH1和IDH2基因突变,会导致细胞产生一种刺激癌症生长的代谢物质。重复研究还证实了白血病细胞中该代谢物质的水平可揭示癌症患者是否存在IDH变异。(该论文原创作者是美国纽约市纪念斯隆—凯特林癌症中心的Craig Thompson。)

此次进行的另一项重复性研究检查了2011年发表于《自然》的一项关于BET阻凝剂的研究,该化合物可控制基因是否被激活并能阻止一种白血病。在最初研究中,I-BET151化合物杀死了培养皿中的人类白血病细胞并减少了它们在小鼠体内的数量。然而,与原论文不同的是,那些小鼠并没有比未经治疗的罹患白血病的小鼠生存得更久。

原始出处

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1973009, encodeId=ac1b19e300947, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 07 20:18:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751554, encodeId=dc911e51554cd, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Thu Dec 21 22:18:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068510, encodeId=c5462068510c1, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Sep 28 18:18:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514175, encodeId=397215141e553, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jul 01 04:18:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216700, encodeId=d213216e0075, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 29 14:58:03 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
    2018-02-07 膀胱癌
  2. [GetPortalCommentsPageByObjectIdResponse(id=1973009, encodeId=ac1b19e300947, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 07 20:18:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751554, encodeId=dc911e51554cd, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Thu Dec 21 22:18:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068510, encodeId=c5462068510c1, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Sep 28 18:18:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514175, encodeId=397215141e553, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jul 01 04:18:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216700, encodeId=d213216e0075, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 29 14:58:03 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
    2017-12-21 珙桐
  3. [GetPortalCommentsPageByObjectIdResponse(id=1973009, encodeId=ac1b19e300947, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 07 20:18:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751554, encodeId=dc911e51554cd, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Thu Dec 21 22:18:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068510, encodeId=c5462068510c1, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Sep 28 18:18:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514175, encodeId=397215141e553, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jul 01 04:18:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216700, encodeId=d213216e0075, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 29 14:58:03 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
    2017-09-28 clmlylxy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1973009, encodeId=ac1b19e300947, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 07 20:18:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751554, encodeId=dc911e51554cd, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Thu Dec 21 22:18:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068510, encodeId=c5462068510c1, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Sep 28 18:18:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514175, encodeId=397215141e553, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jul 01 04:18:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216700, encodeId=d213216e0075, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 29 14:58:03 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1973009, encodeId=ac1b19e300947, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 07 20:18:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751554, encodeId=dc911e51554cd, content=<a href='/topic/show?id=713d95e399f' target=_blank style='color:#2F92EE;'>#重复性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95739, encryptionId=713d95e399f, topicName=重复性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ced636322728, createdName=珙桐, createdTime=Thu Dec 21 22:18:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068510, encodeId=c5462068510c1, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Sep 28 18:18:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514175, encodeId=397215141e553, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jul 01 04:18:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216700, encodeId=d213216e0075, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Thu Jun 29 14:58:03 CST 2017, time=2017-06-29, status=1, ipAttribution=)]
    2017-06-29 130****4638

    学习了谢谢分享

    0

相关资讯

Proc Natl Acad Sci U S A:甲基化“印记”可作为癌症诊疗、预后的重要指标

6月26日,《PNAS》期刊在线发表一篇题为“DNA methylation markers for diagnosis and prognosis of common cancers”的文章,揭示DNA甲基化可以作为常见癌症的诊断和预后的重要标记物。

Cell:地西他滨帮助免疫疗法突破瓶颈,把癌细胞“赶尽杀绝”

圣裘德儿童医院免疫学家们发现了免疫细胞T细胞如何变得“筋疲力尽”,无法完成抵御外部细菌,癌细胞以及病毒侵入工作的原理,这一发现很重要,因为免疫疗法有时对癌症患者无反应,或者癌症易复发,这可能都是T细胞疲劳造成的结果。在此次研究中,科学家们发现,已经在使用的化疗药物可以扭转T细胞的疲劳。

基因测试帮助识别与癌症相关的25种基因突变

有没有人知道DNA突变与癌症发展的关系,虽然这个原因有点儿令人绝望,但是很多临床医生不得不承认,基因突变是造成很多致命疾病的关键因素。

腰围、臀围都会影响罹癌的风险

肥胖是仅次于吸烟的第二项可被预防的癌症危险因子(注 1),而且与大肠癌、乳癌、胰脏癌等 13 种癌症都有关。最近一项研究发现,以腰围为预测罹癌风险的指标,效果与 BMI 值相当。

Cancer cell:癌症如何将身体的“卫士”变为“间谍”

在正常情况下,CHD4蛋白是身体中的“卫士”,它阻止细胞转录错误的DNA,从而消除潜在的突变。但是在结肠癌和其他癌症中,这一蛋白显示出 “双重身份”,它会关闭抑癌基因的表达,为敌人(癌症)而工作。

Cancer:循环代谢物有望成为癌症检测新标记

结肠腺瘤息肉(PLPs)患者很有很大可能性会发展为结直肠癌(CRC)。然而,用于筛查、监督和早期检测结肠腺瘤息肉和结直肠癌的有效方法和生物标志物,对我们来说仍然是一项巨大的挑战。此项研究旨在通过对癌症不同发展阶段的人类血清样本进行代谢组学分析,进而探明结直肠癌的有效生物标志物。